Korean Journal of Clinical Laboratory Science (대한임상검사과학회지)

Korean Society for Clinical Laboratory Science (대한임상검사과학회)
권호 표지
DOI QR코드

DOI QR Code

Serum Uric Acid to Creatinine Ratio as a Predictor of Metabolic Syndrome in Healthy Adults Men

건강한 성인 남성의 대사증후군 위험 예측인자로서 혈청 요산/크레아티닌 비율

  • Kim, Myong Soo (Department of Laboratory Medicine, Samsung Medical Center) ;
  • Shin, Kyung A (Department of Clinical Laboratory Science, Shinsung University)
  • 김명수 (삼성서울병원 진단검사의학과) ;
  • 신경아 (신성대학교 임상병리과)
  • Received : 2019.01.02
  • Accepted : 2019.02.13
  • Published : 2019.03.31
Download PDF
⟨ Previous Next ⟩

Abstract

This study compared the utility of the serum uric acid/creatinine ratio with that of uric acid as a risk predictor of metabolic syndrome. From November 2016 to October 2018, 14,190 adult men under the age of 20 years, who underwent a comprehensive health checkup at a general hospital in their metropolitan area, were included. Metabolic syndrome was assessed according to the American Heart Association/National Heart Lung and Blood Institute (AHA/NHLBI) criteria. Abdominal obesity was based on the WHO criteria in the Western Pacific region. The serum uric acid/creatinine ratio was found to be higher in the fourth quartile than in the first quartile, with a high incidence of metabolic syndrome and metabolic syndrome components. On the other hand, ROC analysis revealed the serum uric acid/creatinine ratio to be a similar indicator of the metabolic syndrome risk to serum uric acid (AUC, 0.554 vs 0.566). The serum uric acid/creatinine ratio showed lower sensitivity and higher specificity than uric acid. In conclusion, the utility of the serum uric acid/creatinine ratio as an independent indicator to predict the risk of metabolic syndrome is limited, and should be used only as an auxiliary marker.

이 연구는 대사증후군 위험 예측인자로서 요산과 비교하여 혈청 요산/크레아티닌 비율의 유용성을 확인하고자 하였다. 2016년 11월부터 2018년 10월까지 수도권 소재의 일개 종합병원에서 종합건강검진을 받은 20세 이상 80세 미만의 성인 남성 14,190명을 대상으로 하였다. 대사증후군 진단기준은 American Heart Association/National Heart Lung and Blood Institute (AHA/NHLBI)의 기준에 따라 5가지 대사증후군 구성요소 중 3가지 이상 해당되는 경우 대사증후군을 평가하였으며, 이 중 복부비만은 WHO 서태평양지역의 기준에 따랐다. 이 연구결과 혈청 요산/크레아티닌 비율은 1사분위수보다 4사분위수의 대사증후군 및 대사증후군 구성요소의 높은 발생빈도를 보였다. 그러나 ROC 분석 결과 혈청 요산/크레아티닌 비율은 대사증후군 위험 예측에 있어 혈청 요산치보다 더 유용한 지표는 아니었으며(AUC, 0.554 vs 0.566), 요산치보다 낮은 민감도와 높은 특이도를 보였다. 결론적으로 혈청 요산/크레아티닌 비율의 유용성을 확인한 결과 대사증후군 위험을 예측하는 독립적인 지표로 사용하는데 제한이 있으며, 보조적인 표지자로 사용하는 것이 바람직하겠다.

Keywords

References

  1. Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009;120:1640-1645. https://doi.org/10.1161/CIRCULATIONAHA.109.192644.
  2. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA. 2001;285:2486-2497. https://doi.org/10.1001/jama.285.19.2486
  3. Alberti KG, Zimmet P, Shaw J, IDF Epidemiology Task Force Consensus Group. The metabolic syndrome-a new worldwide definition. Lancet. 2005;366:1059-1062. https://doi.org/10.1016/S0140-6736(05)67402-8
  4. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med. 1998;15:539-553. https://doi.org/10.1002/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO;2-S.
  5. Alberti KG, Zimmet P, Shaw J. Metabolic syndrome-a new world-wide definition. A Consensus Statement from the International Diabetes Federation. Diabet Med. 2006;23:469-480. https://doi.org/10.1111/j.1464-5491.2006.01858.x.
  6. Shin KA. Association of metabolic syndrome with exercise capacity and heart rate recovery after treadmill exercise test. J Exp Biomed Sci. 2011;17:305-311.
  7. Shin KA. Association between resting heart rate and risk factors of metabolic syndrome in Korean men. The Journal of Korea Society for Wellness. 2015;10: 305-316.
  8. Shin KA. Relationship between metabolic syndrome and pulmonary function in nonsmoker male. The Journal of the Korea Contents Association. 2014;14: 313-321. http://doi.org/10.5392/JKCA.2014.14.12.313.
  9. Shin KA. The relationship between metabolic syndrome risk factors and high sensitive C-reactive protein in abdominal obesity elderly women. Korean J Clin Lab Sci. 2017;49:121-127. https://doi.org/10.15324/kjcls.2017.49.2.121.
  10. Thomas G, Sehgal AR, Kashyap SR, Srinivas TR, Kirwan JP, Navaneethan SD. Metabolic syndrome and kidney disease: a systematic review and meta-analysis. Clin J Am Soc Nephrol. 2011;6:2364-2373. https://doi.org/10.2215/CJN.02180311.
  11. Al-Daghri NM, Al-Attas OS, Wani K, Sabico S, Alokail MS. Serum uric acid to creatinine ratio and risk of metabolic syndrome in Saudi type 2 diabetic patients. Sci Rep. 2017;7:12104. https://doi.org/10.1038/s41598-017-12085-0.
  12. Dalton RN. Serum creatinine and glomerular filtration rate: perception and reality. Clin Chem. 2010;56:687-689. https://doi.org/10.1373/clinchem.2010.144261.
  13. Muntner P, He J, Hamm L, Loria C, Whelton PK. Renal insufficiency and subsequent death resulting from cardiovascular disease in the United States. J Am Soc Nephrol. 2002;13:745-753. https://doi.org/10.1681/ASN.V133745
  14. Chang IH, Han JH, Myung SC, Kwak KW, Kim TH, Park SW, et al. Association between metabolic syndrome and chronic kidney disease in the Korean population. Nephrology (Carlton). 2009;14:321-326. https://doi.org/10.1111/j.1440-1797.2009.01091.x.
  15. Johnson RJ, Feig DI, Herrera-Acosta J, Kang DH. Resurrection of uric acid as a causal risk factor in essential hypertension. Hypertension. 2005;45:18-20. https://doi.org/10.1161/01.HYP.0000150785.39055.e8.
  16. Nakagawa T, Hu H, Zharikov S, Tuttle KR, Short RA, Glushakova O, et al. A causal role for uric acid in fructose-induced metabolic syndrome. Am J Physiol Renal Physiol. 2006;290:F625-F631. https://doi.org/10.1152/ajprenal.00140.2005.
  17. Johnson RJ, Kang DH, Feig D, Kivlighn S, Kanellis J, Watanabe S, et al. Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease? Hypertension. 2003;41:1183-1190. https://doi.org/10.1161/01.HYP.0000069700.62727.C5.
  18. Quinones Galvan A, Natali A, Baldi S, Frascerra S, Sanna G, Ciociaro D, et al. Effect of insulin on uric acid excretion in humans. Am J Physiol. 1995;268(1 Pt 1):E1-5. https://doi.org/10.1152/ajpendo.1995.268.1.E1.
  19. Gu L, Huang L, Wu H, Lou Q, Bian R. Serum uric acid to creatinine ratio: A predictor of incident chronic kidney disease in type 2 diabetes mellitus patients with preserved kidney function. Diab Vasc Dis Res. 2017;14:221-225. https://doi.org/10.1177/1479164116680318.
  20. Shin SR, Han AL. Relationship between metabolic syndrome and uric acid to creatinine ratio in Korean adults: Korea National Health and Nutrition Examination Survey 2016. Korean J Health Promot. 2018;18:113-118. https://doi.org/10.15384/kjhp.2018.18.3.113.
  21. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation. 2005;112:2735-2752. https://doi.org/10.1161/CIRCULATIONAHA.105.169404.
  22. World Health Organization regional office for the Western Pacific, International Diabetes Institute, International Association for the Study of Obesity, International Obesity Task Force. The Asia-Pacific perspective: redefining obesity and its treatment [Internet]. Sydney: Health Communications Australia; 2000 [cited 2019 February 16]. Available from: http://www.wpro.who.int/nutrition/documents/docs/Redefiningobesity.pdf.
  23. Rathmann W, Funkhouser E, Dyer AR, Roseman JM. Relations of hyperuricemia with the various components of the insulin resistance syndrome in young black and white adults: the CARDIA study. Coronary Artery Risk Development in Young Adults. Ann Epidemiol. 1998;8:250-261. https://doi.org/10.1016/S1047-2797(97)00204-4
  24. Conen D, Wietlisbach V, Bovet P, Shamlaye C, Riesen W, Paccaud F, et al. Prevalence of hyperuricemia and relation of serum uric acid with cardiovascular risk factors in a developing country. BMC Public Health. 2004;4:9. https://doi.org/10.1186/1471-2458-4-9.
  25. Kodama S, Saito K, Yachi Y, Asumi M, Sugawara A, Totsuka K, et al. Association between serum uric acid and development of type 2 diabetes. Diabetes Care. 2009;32:1737-1742. https://doi.org/10.2337/dc09-0288.
  26. Zhang L, Wang F, Wang X, Liu L, Wang H. The association between plasma uric acid and renal function decline in a Chinese population-based cohort. Nephrol Dial Transplant. 2012;27:1836-1839. https://doi.org/10.1093/ndt/gfr597.
  27. Zoppini G, Targher G, Chonchol M, Ortalda V, Abaterusso C, Pichiri I, et al. Serum uric acid levels and incident chronic kidney disease in patients with type 2 diabetes and preserved kidney function. Diabetes Care. 2012;35:99-104. https://doi.org/10.2337/dc11-1346.
  28. Goicoechea M, de Vinuesa SG, Verdalles U, Ruiz-Caro C, Ampuero J, Rincon A, et al. Effect of allopurinol in chronic kidney disease progression and cardiovascular risk. Clin J Am Soc Nephrol. 2010;5:1388-1393. https://doi.org/10.2215/CJN.01580210.
  29. Madero M, Sarnak MJ, Wang X, Greene T, Beck GJ, Kusek JW, et al. Uric acid and long-term outcomes in CKD. Am J Kidney Dis. 2009;53:796-803. https://doi.org/10.1053/j.ajkd.2008.12.021.
  30. Sturm G, Kollerits B, Neyer U, Ritz E, Kronenberg F; MMKD Study Group. Uric acid as a risk factor for progression of non-diabetic chronic kidney disease? the Mild to Moderate Kidney Disease (MMKD) Study. Exp Gerontol. 2008;43:347-352. https://doi.org/10.1016/j.exger.2008.01.006.
  31. Jalal DI, Chonchol M, Chen W, Targher G. Uric acid as a target of therapy in CKD. Am J Kidney Dis. 2013;61:134-146. https://doi.org/10.1053/j.ajkd.2012.07.021.
  32. Jalal DI, Maahs DM, Hovind P, Nakagawa T. Uric acid as a mediator of diabetic nephropathy. Semin Nephrol. 2011;31:459-465. https://doi.org/10.1016/j.semnephrol.2011.08.011.
  33. Facchini F, Chen YD, Hollenbeck CB, Reaven GM. Relationship between resistance to insulin-mediated glucose uptake, urinary uric acid clearance, and plasma uric acid concentration. JAMA. 1991;266:3008-3011. https://doi.org/10.1001/jama.1991.03470210076036
  34. Li M, Gu L, Yang J, Lou Q. Serum uric acid to creatinine ratio correlates with ${\beta}$-cell function in type 2 diabetes. Diabetes Metab Res Rev. 2018;34:e3001. https://doi.org/10.1002/dmrr.3001.
  35. Shin KA. Clinical usefulness of serum uric acid and resting heart rate in the diagnosis of metabolic syndrome in Korean adults. Biomed Sci Letters. 2017;23:118-127. https://doi.org/10.15616/BSL.2017.23.2.118.
  36. Lee CH, Sung NY. The prevalence and features of Korean gout patients using the National Health Insurance Corporation Database. J Rheum Dis. 2011;18:94-100. https://doi.org/10.4078/jrd.2011.18.2.94.